+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency



Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency



International Journal of Chronic Obstructive Pulmonary Disease 13: 3645-3649



Endobronchial coil treatment (ECT) is a minimally invasive procedure developed for palliative care of patients with severe emphysema. ECT has demonstrated a decrease in hyperinflation, an improvement in quality of life, and an acceptable safety profile in randomized controlled trials (RCTs). Because alpha-1 antitrypsin deficiency (AATD) is a classical exclusion criterion in RCTs, there is no available data for ECT in AATD. In this post hoc analysis of the REVOLENS study (Réduction volumique endobronchique par spirales; ClinicalTrials.gov Identifier: NCT01822795), a multicenter 1:1 RCT which compared bilateral ECT with usual care in severe emphysema, we analyzed the efficacy and safety results at 1 year in six patients with AATD (five males, one female; mean age: 52±9 years) who underwent ECT. A significant decrease in hyperinflation (0.35 L decrease in residual volume [RV]) was observed in four out of six patients at 6 months and three out of six patients at 12 months, and an improvement in quality of life (improvement of 4 points in the St George's Respiratory Questionnaire [SGRQ]) was observed in four out of six patients at both 6 and 12 months. Efficacy results at 6 and 12 months from the six AATD patients were compared with 84 non-AATD patients who underwent ECT, and no statistically significant differences were found for FEV1, RV, 6MWT score and SGRQ score. Respiratory-related serious adverse event was limited to pneumonia in one AATD patient at 1 year post-ECT. This post hoc study suggests that AATD patients may have similar efficacy and safety outcomes at 1 year as non-AATD patients. Because of the paucity of available data, appropriately powered studies are needed to determine the effects of ECT in AATD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065773069

Download citation: RISBibTeXText

PMID: 30464447

DOI: 10.2147/copd.s176366


Related references

Endobronchial valve deployment in severe α-1 antitrypsin deficiency emphysema: a case series. Clinical Respiratory Journal 7(1): 45-52, 2013

Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema. Current Medical Research and Opinion 34(11): 1927-1932, 2018

Patient-specific goals significantly improve after endobronchial coil treatment in patients with severe emphysema. Clinical Respiratory Journal 12(6): 2157-2158, 2018

Gas exchange during exercise in patients with severe alpha-1-antitrypsin deficiency emphysema. Atemwegs- und Lungenkrankheiten 21(6): 323-324, 1995

Atrophy, asthma, and emphysema in patients with severe alpha-1-antitrypsin deficiency. American Journal of Respiratory & Critical Care Medicine 156(1): 68-74, 1997

Liver function in patients with alpha 1 antitrypsin deficiency and severe pulmonary emphysema. Gastroenterology 102(4 Part 2): A907, 1992

Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (Pi ZZ). Digestion 57(3): 165-169, 1996

A comparative ultrastructural and molecular biological study on Chlamydia psittaci infection in alpha-1 antitrypsin deficiency and non-alpha-1 antitrypsin deficiency emphysema versus lung tissue of patients with hamartochondroma. Bmc Infectious Diseases 4: 38, 2004

Nutritional status and muscle strength in patients with emphysema and severe alpha(1)-antitrypsin deficiency. Chest 122(4): 1240-1246, 2002

Effectiveness of endobronchial coil treatment for lung volume reduction in patients with severe heterogeneous emphysema and bilateral incomplete fissures: a six-month follow-up. Respiration; International Review of Thoracic Diseases 88(1): 52-60, 2014

Normal diffusing capacity in patients with PiZ alpha(1)-antitrypsin deficiency, severe airflow obstruction, and significant radiographic emphysema. Chest 118(3): 867-871, 2000

Substitution of alpha 1-antitrypsin in patients with pulmonary emphysema and alpha 1-antitrypsin deficiency. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 94: 6, 1988

Alpha-1 antitrypsin deficiency with severe pulmonary emphysema. Internal Medicine 43(3): 223-226, 2004

Liver changes in adults with alpha-1-antitrypsin deficiency and severe emphysema. Ugeskrift for Laeger 135(46): 2515-2517, 1973

Epidemiology of emphysema in subjects with severe alpha 1-antitrypsin deficiency. Danish Medical Bulletin 49(2): 145-158, 2002